Venky's (India): The Poultry Cycle Inside the Group

I. The quarter the prices turned

In November 2025, the managers of Venky's (India) Limited dialled into a conference call with little good news to share. For six months the market had moved against them. A day-old broiler chick, the company's most basic product, was selling for ₹11 less than a year earlier. A kilogram of live commercial broiler bird had fallen by ₹18.² Feed was cheaper, which should have helped, but the cheaper feed did not make up for the lower selling prices. In the first half of the fiscal year, the company posted a net loss of about ₹11 crore.⁵

Six months later the picture had changed. Realizations for chicks and broilers recovered in the second half. On the May 2026 call, the tone was easier.³ Venky's (India) Limited closed FY26 with revenue of about ₹3,727 crore, total profit of ₹135 crore, and operating cash flow of ₹191 crore. That last figure was almost three times the previous year's.¹

This story asks what that recovery means. Was FY26 the start of a lasting recovery? Or was it one good stretch of quarters in a business where the selling price can outweigh everything else, including cost discipline, brand, scale and management effort?

The name needs some care. Most Indian consumers know "Venky's" as a large poultry brand. To many sports fans abroad it means the family that bought an English football club. Neither picture describes the listed company. Venky's (India) Limited, which this article calls VIL, is an NSE-listed operating company. Its controlling shareholder is a private company, Venkateshwara Hatcheries Private Limited (VHPL), which held 51.61% of VIL at March 2025. The wider promoter group held 55.54%.⁴ Around both of them sits the VH Group, a family of companies with breeding, research, feed, food and other businesses. Many of those businesses sit outside the listed company's accounts.⁵

That boundary matters because VHPL does more than own VIL. It also buys from VIL, sells to it, and owes it money. A shareholder who buys VIL stock owns a minority share of a company that sits inside a larger family system. The listed company's results depend partly on market forces and partly on decisions made by its own controlling shareholder.

Four questions run through this story.

First, who captures the value inside the group? When VIL sells chicks, medicines or soy meal to group companies, does the listed company earn a fair return, and does it collect the cash?

Second, can VIL make money across the full poultry cycle, or only when prices are high?

Third, can Animal Health Products and oilseeds keep supplying the earnings that steadied FY26?

Fourth, do the group receivables and the company's investments deserve a minority shareholder's trust?

One fact from FY26 frames all four. Poultry was VIL's largest segment by revenue at about ₹1,897 crore. The largest segment profit came from Animal Health Products, a much smaller business with about ₹392 crore of revenue and a segment result of about ₹99 crore. Poultry's result was about ₹65 crore.¹ A business with roughly a fifth of poultry's revenue earned half again as much segment profit.

That changes the usual description of the company. VIL is more than a poultry company with some side businesses. It is a set of businesses with very different economics, sitting under one brand inside a larger group. To understand that structure, the story starts with a deal from 2014.

↑ Back to Top

II. The 2014 deal that moved the map

On 12 March 2014, VIL's board met and approved a transfer that changed the company's footprint. VIL agreed to buy poultry and related operations in northern India from its holding company, VHPL.⁸ The acquisition took effect on 31 March 2014, the last day of the fiscal year.⁷

The total cost was about ₹75 crore. VIL booked about ₹15.85 crore of goodwill, which is the amount paid above the fair value of the identifiable assets it received.⁷ Those numbers look small next to today's ₹3,700-crore revenue. In 2014 the deal was material: it extended VIL's poultry operations into territory that had been run by the parent.

The logic was easy to follow. Poultry is a regional business. Day-old chicks are perishable, and a live broiler cannot be shipped across the country as cheaply as a bag of soy meal. Hatcheries, breeder farms and distribution networks have to be close to the farmers who grow the birds. Before the transfer, the group's northern operations sat in a private company where VIL's public shareholders had no direct stake. After it, they sat inside the listed entity. Management described the deal as a way to consolidate the group's poultry operations and widen VIL's geographic reach.⁷

Related-party deals of this kind always raise a question. Is the parent moving a strong business into the listed company to share its value with minorities, or moving a weaker business in at a full price to turn its own assets into cash? The 2014 records offer some evidence on this. The fixed assets were independently valued.⁷ That is good practice, and it gives some assurance that buildings, land and equipment were not marked up arbitrarily.

An asset valuation and a fair price are different things, though. A valuer can confirm that a hatchery's equipment is worth a certain amount without saying whether the whole business deserved a premium of ₹15.85 crore in goodwill. The useful test would be a set of comparable deals: what other Indian poultry integrators paid for regional operations at the time, measured against revenue, profit or capacity. Those comparisons do not appear in the company's disclosures. The fair conclusion is narrow. The deal had a clear operating reason and a proper valuation process. Nobody can show it was a bargain or an overpayment.

It is also, as far as VIL's own accounts show, the only acquisition of this size. VIL has made no large external acquisition in its recent record. The VH Group's ventures and purchases elsewhere happened above or beside the listed company, and they tell an investor where the family puts its effort, not what VIL owns. One related-party asset transfer does not establish a pattern of disciplined acquisitions.

The longer history can be covered briefly. VIL traces its origins to 1976.⁷ It grew alongside India's shift from backyard chicken to industrial broiler production, when hatcheries, commercial feed and contract farming changed how protein reached Indian kitchens. For an investor, the earlier decades matter mainly because they produced the brand and the operating know-how. The investment questions start with the 2014 consolidation, the volatile earnings that followed, and the change in which segments make the profit.

Capital history adds a little. Paid-up equity was about ₹14.09 crore at both March 2024 and March 2025.⁴ FY26's cash flow statement shows no share issuance, no buyback and no debenture issue.¹ VIL has not been diluting shareholders to pay for growth. Its capital structure has stayed stable, and its interesting financial flows run through its trade with the group.

The 2014 deal moved operations onto VIL's books. It could not give VIL control over the price of a chick, and that price drives the next part of the story.

↑ Back to Top

III. The chick price is the plot

On the November 2025 call, an analyst asked the question every poultry investor eventually asks. Maize and soy, the two main feed ingredients, had become cheaper. Feed is the largest cost in raising a broiler. So why was VIL still losing money?

Management answered with selling prices. Realizations for chicks and broilers had fallen so far that lower feed costs could not make up the difference. Management estimated the impact of lower realizations at about ₹140 crore.² Over the first half, VIL realized an average of about ₹81 per kilogram of broiler bird, while its production cost was roughly ₹85–86 per kilogram.² Every kilogram it sold lost money.

That exchange explains the business better than any brand campaign. VIL does not set the price of chicken. Supply, demand and the timing of placements across the industry set it, and in the short run that timing hardly responds to any one company.

The units that matter

It helps to know what VIL sells and how each product is priced.

The day-old chick is sold to farmers, often contract growers, who raise it for about six weeks. Its price is quoted per chick and moves with expected broiler prices. When farmers expect weak bird prices, they buy fewer chicks and chick prices collapse.

The broiler bird is the grown chicken, sold live and priced per kilogram. This is the main market price. It rises in festival seasons and winter, and it falls when there is too much supply, when demand is weak during religious fasting periods, or when consumers are frightened by a bird-flu scare. In early 2025, reports of bird flu helped push chicken prices down sharply in parts of India.¹⁵

The hatching egg is an egg intended to become a chick rather than breakfast. It sits upstream and moves with the chick market.

Feed is the input. Maize supplies energy and soybean meal supplies protein. Their prices depend on monsoon rainfall, crop sizes, government policy and global oilseed markets.

A broiler integrator's profit is roughly the gap between the bird price and the feed-driven cost of raising the bird. Both sides move, and they do not move together. In good years, feed is cheap and chicken is expensive. In bad years, both can go wrong at once. The November 2025 situation was an awkward middle case: costs had eased and prices had fallen even further. In VIL's poultry business, a lower feed bill cannot make up for a low selling price.

Ten years of evidence

The long record shows the same pattern. Sales grew from about ₹2,127 crore in FY16 to about ₹3,727 crore in FY26, a compound growth rate of roughly 6% a year.⁶ Profit rose from about ₹38 crore to about ₹139 crore on the aggregator's basis.⁶ On those endpoints, VIL looks like a steady compounder.

The years in between do not. VIL lost money in FY20 and then posted a profit peak in FY21.⁶ FY25 was a recovery year, H1 FY26 was a loss, and H2 FY26 was another recovery. Revenue over the decade grew a little slower than India's poultry demand is often said to grow, and profits moved with the cycle rather than with demand. FY26's sales growth of about 13% over FY25 only took revenue back to roughly where it stood in FY24.⁶

So long-run demand for chicken in India is real. Rising incomes, urbanization, and chicken's place as one of the most widely accepted meats across religions all support volume growth. Management says it expects the poultry business to grow at about the industry's rate of 7–8%.³ Volume growth is not profit growth. Ten years of VIL's own numbers show that the cycle decides earnings.

The competitive field

VIL competes in a crowded field with no clear boundaries. Suguna Foods, the Coimbatore-based integrator, is often described as the largest player. An Asian Development Bank project document put its share at about 15% of India's broiler market in FY19.¹⁰ IB Group, Godrej Tyson and many regional integrators also compete, alongside thousands of small farmers and traders who sell live birds into local markets. ICRA's analysis of the industry describes a fragmented market where pricing follows the industry cycle and integrated players' margins move with feed costs and realizations.⁹

Comparable current market shares for VIL and its peers are not published. That gap matters. A company with a 15% share in a market of thousands of sellers does not set prices. It accepts them.

The forces at work

Porter's framework fits poultry well.

Buyer power is high. Farmers buying chicks and traders buying birds can switch to another hatchery or wholesaler. One kilogram of live broiler is largely interchangeable with another. Brand matters more for processed and packaged products than for live birds.

Supplier power comes from nature and commodity markets rather than from a few dominant vendors. Maize and soy prices depend on the monsoon and global trade. Disease is its own kind of supplier risk: an avian influenza outbreak can cut demand and force culling at the same time.

Barriers to entry are moderate. Breeding stock, biosecurity, hatchery operations and distribution networks take years to build, so a newcomer cannot copy an integrator quickly. The barriers protect the incumbents' ability to produce. They do not protect prices, because the market is already full of capacity.

Rivalry is intense in downturns, when everyone holds birds that must be sold before they grow past their ideal weight. A live broiler cannot be stored. Overproduction has to be sold at whatever price clears the market.

Substitutes include eggs, fish, mutton and plant protein. Chicken's price advantage is part of what drives its demand, which limits how far producers can raise prices even in good years.

The upstream claim, tested

The bull case often relies on the group's upstream strength. The VH Group is known for its breeding and research work, including parent stock and veterinary capabilities. CARE describes the group's pan-India footprint and its veterinary and R&D resources.⁵ The investor's question is whether those capabilities belong to VIL.

They mostly do not. VH Group affiliates own much of the breeding and research. VIL is a downstream listed operator that trades heavily with those affiliates.⁴ When a group capability sits in a private company, the listed company gets it only through transfer prices and intercompany arrangements. Whether VIL captures that value, or pays for it, depends on terms the minority shareholder does not negotiate.

The regulator's question

That upstream structure is now being examined by a regulator. On 1 April 2026, India's Competition Commission ordered an investigation into the VH Group after a complaint by People for Animals, the animal-welfare organization founded by Maneka Gandhi.¹²¹³ The case, numbered 15 of 2025, concerns alleged restrictions in breeder agreements: the contracts under which parent birds are supplied to hatcheries and farms.¹¹ The order named VIL alongside group entities.¹¹

At this stage these are allegations, not findings. A direction to investigate means the Commission saw enough to ask its Director General to look further. It is not a ruling that the law was broken. On the May 2026 call, management said the practices concerned parent breeding farms and that VIL did not deal in those products.³ If that is accurate, any eventual penalty or remedy would fall mainly outside the listed company.

Investors should not take either account on trust. The Director General's report, the agreements themselves, and the Commission's final order will settle how much of this belongs to VIL. The probe also highlights an issue that runs through this story: inside a group, the line between the listed company and its affiliates is a legal fact that has economic consequences. If breeder agreements were found to restrict competition, that would also bear on how much of the group's upstream strength comes from capability and how much from contract terms.

The verdict

VIL's integration, brand and expertise help it produce birds efficiently and distribute them widely. Its own record shows that these advantages have not protected it from the cycle. FY20's loss, H1 FY26's loss and the ₹140 crore realization impact all point the same way. On the evidence, VIL has strong operating capabilities in a market where it takes prices. Its moat is not cycle-proof. The KPI that would change this verdict is poultry realization measured against production cost across a full season, not a single quarter.

If poultry cannot steady the company, something else has to. In FY26, two other businesses did much of that work.

↑ Back to Top

IV. The revenue is split three ways; the profits are not

The FY26 segment table is one of the most informative pages VIL publishes.

The revenue column looks the way most people expect. Poultry and poultry products earned about ₹1,897 crore. Solvent extraction, the oilseed business, earned about ₹1,554 crore. Animal Health Products earned about ₹392 crore.¹

The segment result column reverses the order. Animal Health Products earned about ₹99 crore. Poultry earned about ₹65 crore. Oilseeds earned about ₹54 crore.¹

Two definitions matter here. Segment revenue is reported before inter-segment eliminations, so sales between VIL's own divisions, such as oilseed meal going into poultry feed, are included at the segment level and removed in the company total. Segment result is measured before finance costs and before unallocated corporate items. It is not net profit for each business. It is the best available view of which business produces operating earnings.

On that view, Animal Health Products earned roughly a 25% segment margin on revenue. Poultry earned about 3.4% and oilseeds about 3.5%.¹ Those are very different kinds of business. Poultry and oilseeds handle large volumes of low-margin commodities. Animal Health Products earns margins closer to those of a specialty products company.

What Animal Health Products is

Animal Health Products sells medicines, vaccines, feed supplements and related products for poultry and other animals. Its customers are farmers, integrators and veterinarians who want to keep flocks healthy and growing efficiently. A poultry farmer losing birds to infection, or seeing poor feed conversion, will pay for products that fix the problem. In this segment, technical service and trust can support a better price than a commodity bird can.

Management credits several factors for the improvement: a better product mix, a new therapeutic manufacturing facility, wider distribution, and technical support teams that help customers use the products.³ These are plausible sources of advantage. A field team that visits farms and diagnoses problems creates a relationship that a pure commodity seller does not have.

The claim needs the same test as everything else, and one fact limits it. On the November 2025 call, management said that about 55% of Animal Health Products sales went to group companies and about 45% to outside customers.² The segment with the best margin sold most of its output inside the family.

That does not make the margins false. Group companies need animal-health products, and buying them from an affiliate can be sensible. It does mean that the segment's revenue and margin depend partly on intercompany transfer prices, and the minority shareholder sees only the result. A rising external share at stable margins would show real market demand. A flat or falling external share would leave open how much of the segment's profitability comes from captive customers.

What oilseeds are

The oilseed business is a commodity processor. VIL crushes soybeans, extracts the oil, and sells soybean oil and de-oiled cake. The cake is a protein-rich meal that becomes animal feed. Some of it goes back into VIL's and the group's poultry feed, and some is sold outside.

Returns depend on three things: the spread between soybean prices and oil and meal prices; capacity utilization, since a crushing plant has heavy fixed costs; and inventory timing, since buying seed before prices fall can wipe out a quarter's margin. In November 2025, management said oilseed and SPF capacity utilization was only around 50–55%.² A plant at half capacity spreads its fixed costs over half the volume.

Oilseeds also act as a partial hedge against poultry. When soy meal is expensive, the poultry feed bill rises, but the oilseed division may earn more on the meal it sells. The hedge is imperfect and the timing rarely matches. It does explain why the group put the two businesses under one roof.

The SPF egg and its utilization record

The most interesting product in the segment table is not shown as a separate line. Specific-pathogen-free eggs, called SPF eggs, are laid by flocks kept under strict biosecurity so that they are free of particular disease agents. Vaccine makers use them to grow viruses for vaccines, including some influenza and veterinary vaccines. Producing them needs sealed facilities, careful flock management and regular testing. Few companies in India can do it.

VIL's SPF business has a story behind it. In June 2021, during the pandemic, the Times of India reported on Venky's special eggs for vaccine production and the company's position in that market.¹⁴ The same coverage recorded a 2020 capacity expansion that was running at about 63% utilization in May 2021. Management then targeted 85% utilization in FY22 and 90% in FY23.¹⁴

On the November 2025 call, management put SPF utilization at roughly 50%.² It also described a new expansion. CARE reported a ₹60 crore SPF project expected to ramp up across FY27–28.⁵

Four and a half years after those targets were set, utilization was lower than when they were announced, and the company was adding more capacity. Several explanations are possible. Pandemic demand faded, vaccine makers may have their own supply, and export certifications take time. None of them changes the fact that the technical ability to make SPF eggs has not yet produced full use of the existing capacity.

This is the main lesson of the SPF business. The ability to make a product and the ability to sell enough of it at a good price are different. VIL's own record shows the gap. The new capacity should be treated as an option, not as an established earnings stream, until utilization, external orders and segment returns show otherwise.

The verdict

VIL is more diversified than its "poultry company" label suggests, and the diversification earned real money in FY26. Animal Health Products was the largest segment profit contributor, and oilseeds produced substantial earnings. Neither removes VIL's exposure to poultry realizations and commodity swings, and the best-margin segment depends heavily on group customers. The next question is about those customers.

↑ Back to Top

V. The group is both customer and counterparty

VIL's March 2025 balance sheet shows a receivable of about ₹346 crore owed by VHPL, VIL's controlling shareholder.⁴

VIL's entire profit for FY25 was about ₹117 crore.⁴ The money owed by its parent was roughly three years of the listed company's earnings.

The scale of group trade

In FY25, VIL sold about ₹1,045 crore of materials and finished goods to related parties, roughly 31.6% of revenue.⁴ It bought about ₹440 crore from them, about 13.4% of revenue.⁴ VHPL alone bought about ₹606 crore of VIL products and sold VIL about ₹66 crore.⁴

That company-wide 31.6% figure is different from the 55% Animal Health Products figure in the previous section. The 55% applies to one segment. The 31.6% applies to all of VIL. Both are large, and they measure different things.

VIL describes these transactions as being in the ordinary course of business and at arm's length.⁴ That is the standard statement, and it may be accurate. Group companies grow birds, run feed mills and process food, so they naturally buy chicks, medicines and meal. Much of the trade probably reflects real operating needs.

The arm's-length statement concerns prices. It does not cover the terms of payment.

The terms of credit

At 31 March 2025, VIL's net outstanding balances with related parties were about ₹466 crore.⁴ VHPL accounted for about ₹346 crore and Uttara Foods and Feeds, another group company, for about ₹93 crore.⁴

These receivables are unsecured and interest-free, generally due within 60 to 150 days.⁴ VIL recorded no impairment provision against related-party balances.⁴ In plain terms, the listed company gives its parent and affiliates months of free credit with no collateral, and books no provision for the risk that some of it might not be paid.

There is also collateral. VIL disclosed about ₹145 crore of collateral security given, for which it earned about ₹1 crore in commission from VHPL.⁴ That is a fee of well under 1% for putting listed-company assets behind another party's obligations.

CARE noticed this too. Its January 2026 rationale named delayed realization of group-company debtors as a factor that could pressure VIL's liquidity, and listed it among the developments that could lead to a downgrade.⁵ That is a credit analyst's warning about this specific mechanism.

The improving side

The trend is improving. Related-party balances fell from about ₹627 crore at March 2024 to ₹466 crore at March 2025.⁴ Total trade receivables also fell, from about ₹715 crore to about ₹554 crore.⁴ Money did come back, and some of FY25's working-capital inflow came from collections. FY26 year-end trade receivables were about ₹544 crore, roughly flat.¹

The aging

Trade receivables also had a tail. At March 2025, about ₹40 crore was outstanding for more than a year, including about ₹10 crore for more than three years.⁴ None was classified as disputed or credit-impaired, and the total impairment provision on trade receivables was about ₹13 crore.⁴ A three-year-old receivable not classified as impaired deserves a question at the next AGM. It may be a slow but reliable payer. It may also be a balance that nobody wants to write off.

The skeptic's challenge

An activist investor would frame it this way. VIL is spending on new SPF and therapeutic capacity and has taken new term loans to do it.⁵ At the same time, it extends hundreds of crores of interest-free credit to its controlling shareholder and pledges collateral for a small fee. If that ₹345 crore were collected and held in a liquid fund, or used to repay debt, the minority shareholder would be better off by its yield. If the group needs the working capital, the listed company could charge interest.

The usual defence is that these terms are normal in the trade and that group customers bring volume. That may be true. VIL could show it by disclosing year-by-year aging and post-year-end collections for each major group receivable, which would replace the defence with evidence.

The verdict

The filings say how much group trade VIL does. That question is answered: about a third of revenue. They do not show whether the credit and collateral VIL provides are good uses of listed-company capital. The direction improved in FY25. The scale remains large, the terms favour the group, and the rating agency has identified this as a downside trigger. In a group company, the invoice is part of the investment case. Whether the money VIL is spending on new capacity will earn its keep is the next question.

↑ Back to Top

VI. New capacity has to earn its way

On the November 2025 call, management described projects that would expand VIL: new SPF capacity, a therapeutic facility in Animal Health Products, and processed-food lines.² On the same call, it said several existing operations were running far below capacity.²

Those two facts together are the tension in this section. Underused assets are a warning sign for any capital-intensive business, and new projects are where future returns will come from.

The scale of investment

VIL is not a heavy spender. In FY25 it spent about ₹46 crore on property, plant, equipment and intangibles, about 1.4% of revenue.⁴ The year before it spent about ₹50 crore.⁴ Reported R&D was about ₹7 crore, about 0.2% of revenue, directed at work on SPF eggs and breeder-related applications.⁴ Headcount rose modestly, from 5,456 to 5,623.⁴

These are maintenance-plus levels of spending. The company is not being stripped for cash, and it is not being reshaped by investment. The ₹60 crore SPF project is large by VIL's standards: more than a full year of normal capex in one line.⁵ CARE also reported about ₹16.20 crore of FY26 spending on processed and frozen foods.⁵

To pay for this, VIL arranged about ₹52 crore of new term facilities, of which about ₹40 crore had not been drawn when CARE wrote its rationale in January 2026.⁵ Leverage stayed low. CARE reported FY25 gearing of about 0.12 times, with no covenant pressure and no refinancing strain.⁵ Borrowings were about ₹165 crore at March 2025, against cash, bank balances and mutual funds of roughly ₹310 crore.⁴ The balance sheet can carry the SPF bet.

The treasury cushion

That cash pile adds something to the earnings picture. Other income was about ₹44 crore in FY25, around 27% of pre-tax profit, and about ₹48 crore in FY26, around a quarter of pre-tax profit.⁴¹ FY25 other income included interest, gains on liquid and debt mutual funds, and government grants.⁴ FY26 current investments rose to about ₹213 crore.¹

The treasury is conservative. The funds were liquid, money-market and banking/PSU debt schemes, not speculative bets.⁴ For an investor, the point is that a quarter of pre-tax profit came from money VIL was not using in operations. That cushions the cycle and flatters the reported operating picture. It also sits awkwardly beside the interest-free credit given to the parent: VIL earns yield on its own surplus cash while lending to its controlling shareholder at zero.

The SPF wager

The rationale for SPF is real. Vaccine manufacturers need reliable, certified egg supply, and the product's technical difficulty limits competition. If VIL can win export customers or long-term domestic vaccine contracts, SPF could earn margins well above poultry's.

The utilization history from the previous section has to sit next to that rationale. Utilization remained low. Before treating new SPF capacity as value, an investor would want signed offtake, export certifications turning into orders, rising utilization and incremental segment margins. Until those appear, the project is a possible future earnings source, not an established one.

What is small

Processed and frozen foods, ready-to-cook products and new consumer lines often appear in VIL's commentary. They make good brand stories: packaged chicken in modern retail, ready meals for city households. VIL does not report them as a separate segment, and nothing in the filings suggests they yet contribute material revenue or profit. Until they do, they should not distract from the three businesses that drive earnings.

The verdict

VIL is investing carefully relative to its size, financed with modest debt and supported by a cash cushion. The returns depend on filling capacity it has already built and finding outside buyers for what it adds. The SPF project is the clearest test of whether VIL can turn technical capability into revenue. That brings the story to the people making these decisions, and whether their record supports trust.

↑ Back to Top

VII. A clean audit does not settle every trust question

On the November 2025 call, an analyst reminded management of an earlier idea: that VIL's three segments might eventually each contribute about one-third of revenue.² Management's answer was firm. Poultry and oilseeds had always been the dominant businesses, it said, and Animal Health Products was growing gradually.²

The exchange was brief, but it showed something about how management talks. By May 2026 the emphasis had changed again. On the Q4 call, management said Animal Health Products and oilseeds had driven much of the year's expansion and EBITDA.³ Analysts will remember messages from one call to the next, and they test whether the strategic story stays consistent.

None of this suggests bad faith. Messages change as businesses change. A management team that adjusts its framing every six months is still harder to hold to targets than one that sets milestones and reports against them. VIL publishes no formal segment targets. That gives it flexibility, and it gives shareholders less to measure it by.

The people

The listed company is led by Managing Director B. Balaji Rao, from the family that controls the VH Group. J.K. Handa served as Chief Financial Officer in FY25.⁴ The board had ten members, five of them independent.⁴

Pay is modest. Balaji Rao received about ₹38 lakh in FY25, slightly less than the about ₹39 lakh of the previous year.⁴ Against FY25 profit of about ₹117 crore, the managing director's pay was a fraction of 1%. Disclosures do not show meaningful equity-linked incentives for executives. The family's alignment comes through ownership. The promoter group held about 55.54% at March 2025.⁴ Exchange data show promoter holding steady at around 56% from September 2023 through June 2026, with promoter shares unpledged at June 2026.⁶¹⁷ Foreign and domestic institutions together held only a few percent.⁶

That structure helps in some ways and hurts in others. The family's wealth rises and falls with VIL's share price, which aligns it with minorities. The same family also controls VHPL, which owes VIL hundreds of crores interest-free. When the controller sits on both sides of a transaction, ownership alignment is incomplete, and the related-party terms are where it is tested.

Earnings into cash

Cash conversion is the real test of reported profit. In FY25, VIL reported profit after tax of about ₹117 crore and operating cash flow of only about ₹66 crore.⁴ Working capital explains most of the gap. Inventory and biological assets absorbed about ₹76 crore, and trade payables and other liabilities fell by about ₹141 crore. Collections from receivables released about ₹140 crore and partly offset those outflows.⁴ Non-cash items also mattered: a gain on current investments of about ₹9 crore and fair-value changes in biological assets of about ₹8 crore increased reported profit without bringing in operating cash.⁴

Biological assets need a short explanation. Under Indian accounting standards, live birds and breeder flocks are carried at fair value, so a change in their estimated value goes through the profit and loss account. That is an accounting judgment. When flock values rise, reported profit can rise before any bird is sold.

FY26 reversed the FY25 pattern. Operating cash flow was about ₹191 crore against total profit of about ₹135 crore.¹ Inventory again absorbed cash, about ₹74 crore, but payables grew by about ₹87 crore and supplied funding.¹ Over the two years, cash flow roughly matched reported profit, but each year looked quite different. Investors should judge conversion over a multi-year period, and they should note that FY26's strength relied partly on stretching suppliers.

The audit record

The FY25 statutory audit opinion was unmodified, and the auditor reported no fraud under section 143(12) of the Companies Act.⁴ Those are real assurances.

The CARO annexure, the auditor's supplementary checklist under Indian law, recorded one specific exception. Company land and buildings with gross carrying values of about ₹4 crore and ₹0.5 crore were still registered in the promoter's name, with transfer to VIL pending because of government regulations.⁴ The amounts are small. The point is that property shown in the listed company's books is legally held by the controlling family. It is a minor exception, but it fits the broader pattern of a group where the boundaries are not fully settled.

VIL also disclosed about ₹27 crore of contingent liabilities at March 2025. The largest piece was about ₹15 crore of disputed excise demands, with smaller income-tax, sales-tax, GST, electricity and labour claims. About ₹9 crore had been paid under protest.⁴ None of this threatens the company, and all of it is routine for an Indian manufacturer.

What still needs checking

The FY26 annual report was published in 2026.¹⁶ Before reaching a firm governance verdict, an investor should check its related-party notes, any change in the CARO title exception, director pay, and the AGM scrutinizer's resolution-by-resolution vote counts. Minority dissent on related-party approvals would be especially informative.

The verdict

The audit is clean, pay is modest, ownership is concentrated, and there is no dilution or pledging. Those are real strengths. The related-party credit, the title exception and the shifting strategic message deserve scrutiny, and the FY25 cash shortfall shows that reported profit and cash can diverge sharply in any single year. Management's record supports reasonable confidence in the reported numbers. It supports less confidence that every capital decision is made with minority shareholders first. With that picture in place, the question is what the stock price assumes.

↑ Back to Top

VIII. What has to be true for the stock to work?

On 1 October 2026, VIL's share price was about ₹1,613, and the stock traded at a price-to-earnings ratio of about 13.1.⁶

That figure has to be read alongside FY26's segment results, which showed how uneven the contributions were.¹ At 13 times earnings, the market is not paying a high premium. It is also not treating these as peak-cycle earnings to be heavily discounted. It is pricing a mix of a cyclical poultry operator and a more stable specialty business, without committing to either view.

What the investor is actually paying for is not clear. It could be a poultry recovery that continues through FY27, a shift toward higher-quality segment earnings, or both. The rest of this section tests each possibility.

Why it may win

The bull case has three parts.

First, VIL has more than one engine. Animal Health Products produced the largest segment result in FY26 at a margin several times poultry's.¹ Management credits a better mix, a new therapeutic plant and wider distribution.³ If that segment keeps growing while poultry swings, group earnings should become steadier over time.

Second, poultry demand is growing. Management expects the poultry business to grow at roughly the industry's 7–8% rate.³ Indian per-capita chicken consumption remains low by global standards, and the long-term volume trend supports integrated operators with established brands and biosecurity.

Third, the balance sheet is a cushion. Gearing is low, treasury assets are substantial, CARE rates the company A+ Stable, and no dilution has been needed.⁵ VIL can survive a bad poultry year without distress, which many smaller rivals cannot.

Why it may not

The bear case also has three parts.

First, FY26's improvement depended on the late-year rebound already described.⁵¹ The decade's swings suggest the next downturn will come.

Second, the best segment is partly captive, as described above.²

Third, capital is tied up with the group and in underused assets. Hundreds of crores sit in interest-free group receivables, collateral backs another party's obligations, and capacity in SPF and oilseeds ran at about half utilization in late 2025.⁴² Those assets could earn more.

The moat analysis

Hamilton Helmer's 7 Powers framework asks which durable advantages let a company earn returns above its cost of capital. Applied to VIL:

Scale economies: some exist in feed milling, hatcheries and distribution. They lower unit costs, but they do not let VIL charge more in a market where thousands of producers set prices. Supported for costs, not for pricing.

Network effects: none in any meaningful sense.

Counter-positioning: none apparent. Rivals can and do copy the integrated model.

Switching costs: low for live birds and chicks. Somewhat higher in Animal Health Products, where technical support and trusted product records make customers reluctant to change. This is the most promising power, and the 55% group share of the segment's sales limits how far it can be proven.

Branding: "Venky's" is widely recognized in India, and CARE cites the established brand as a strength.⁵ In live-bird markets, brand earns little premium. It matters more in processed foods and animal-health products, which are still small or partly captive.

Cornered resource: the most likely candidate is breeding and genetics capability, and that sits largely with VH Group affiliates rather than VIL. SPF technical expertise is real, but utilization does not yet show it to be a scarce resource that commands rents.

Process power: decades of biosecurity and flock management experience probably give VIL operational know-how that is hard to copy. It shows up as resilience and efficiency, not as margin above the cycle.

On this analysis, VIL has some real but partial powers. They are strongest in Animal Health Products and in operating process, and weakest where most of the revenue sits. CARE's own list of constraints, including limited pricing power in a fragmented market, says the same in credit language.⁵

The activist's question

A skeptical long-short investor would focus on one question. Why does a company with surplus treasury funds and new borrowing for capex extend interest-free credit and collateral to its controlling shareholder? What return hurdle justifies that, and what collection record would make it acceptable? A good answer would show year-by-year collections, aging by counterparty and an explicit policy. Without that, the arrangement looks like a cost borne by minority shareholders.

Three KPIs

Three numbers matter most.

Poultry realization against production cost. The latest clear reading was negative, as described above.² This is the cycle indicator.

Animal Health Products' segment result and external-sales share. The latest readings showed continued strength and an external share of about 45%.¹² A rising external share at steady margins would confirm the bull case. A falling one would weaken it.

Related-party receivables and collections. The latest full reading remained high, though it had fallen from the prior year.⁴ The direction was favourable. The size remains large.

The risk radar

Only a few risks are material. The first is the poultry price and feed cycle, already discussed. Disease and weather come next: bird-flu scares and monsoon swings can affect demand and feed costs.¹⁵ Group-debtor delays are the risk CARE flagged.⁵ Underused new investment could weigh on returns. The CCI process remains pending.¹¹

Currency exposure is a smaller item. In FY25, foreign-exchange outflows of about ₹113 crore far exceeded export earnings of about ₹15 crore, which suggests import exposure for inputs or equipment.⁴ VIL reported a small net foreign-exchange gain, and it does not disclose its hedging policy or unhedged positions.⁴ For a company this size, the exposure is manageable, but investors should check whether it changed in FY26.

The verdict

The bull case needs sustained Animal Health Products profits, rising oilseed external sales and a poultry recovery that lasts. The bear case is that volatile realizations, group balances and idle capacity absorb those gains. A P/E of 13 does not decide between them. The next few years of the three KPIs will. Before that, the story has a few lessons.

↑ Back to Top

IX. Lessons from a business that sells into a cycle

Go back to the November 2025 call. Feed had become cheaper, and an analyst asked why the company was still losing money. Management estimated a ₹140 crore hit from lower poultry realizations.² Then set beside it the FY26 segment table, where Animal Health Products, a business with a fifth of poultry's revenue, earned about ₹99 crore.¹ Those two numbers sum up VIL's position. Four lessons follow from them.

Lesson one: a low feed bill cannot rescue a low selling price. Investors in commodity producers tend to watch input costs because they are visible and easy to forecast. VIL's November 2025 losses show that the selling price matters more. Cheaper maize and soy were not enough when chick and broiler prices fell further. For any integrator, look at realization first and cost second. Operating efficiency decides how much a company loses in bad years. It does not stop the bad years.

Lesson two: a second engine matters when it earns, not when it gets a new name. VIL's diversification was not a rebranding exercise. Animal Health Products produced real segment profit in FY26. The SPF story shows the opposite case. Strong technical capability, wide press coverage in 2021, and confident utilization targets were followed by about 50% utilization four years later. When a company announces a new growth engine, ask how much it earns, who buys its output, and whether the capacity it already has is full.

Lesson three: in a group company, the invoice is part of the investment case. About a third of VIL's revenue goes to related parties, and hundreds of crores of receivables sit with its controlling shareholder on interest-free terms. The price on an intercompany invoice decides how profit is divided inside the family. The payment terms decide where the cash stays. A minority shareholder who studies only the income statement misses half the economics. The related-party note is not boilerplate. It shows how value moves between the listed company and its controller.

Lesson four: group capability and listed-company capability are different assets. The VH Group's breeding, research and veterinary reputation is real. Much of it sits outside VIL, and the CCI probe shows how much the legal boundaries matter. Investors who buy "Venky's" for the group's upstream strength need to confirm which entity owns that strength and on what terms the listed company can use it.

These lessons point to what investors should watch next.

↑ Back to Top

X. The next disclosures decide the story

The calendar is what matters now.

VIL reports quarterly, and FY27's second-quarter results, covering July to September 2026, will appear in the coming weeks. The FY26 annual report, with full notes on related parties, receivables aging, the CARO annexure and director pay, is already public.¹⁶ The CCI's Director General is investigating, and its report will eventually go to the Commission for a decision.¹¹

Each of the four central questions has a clear test.

Can poultry earn through the cycle? Watch realizations through a full season, not just the strongest quarter. The test is whether VIL can keep broiler realization above production cost through the monsoon lull and the festival peak. Another H1-style loss would confirm that the cycle still controls the business. Steady positive spreads across both halves would be the first evidence of something stronger.

Are the other two engines durable? Compare Animal Health Products margins and the oilseed division's external sales with what management said on the May 2026 call.³ A rising external share for Animal Health Products would be the clearest evidence that its profits come from the market rather than from intercompany pricing. Oilseed utilization moving from about half toward full would show that the fixed-cost burden is easing.

Does the group pay? Reconcile related-party balances and collateral with cash collections in the FY26 annual report and later disclosures. The improvement from FY24 to FY25 was a start. A further reduction, published aging by counterparty, or interest charged on overdue balances would each strengthen the case. A renewed rise in VHPL balances, especially in a weak poultry year, would point the other way.

Does new capacity earn? Track SPF utilization and any disclosed orders as the ₹60 crore project comes on stream.⁵ The test is simple: does the new capacity fill faster than the old capacity did?

And over all of it hangs the CCI process. A finding that breeder agreements restricted competition, and any remedy, would need to be read carefully for which entity it actually binds.¹¹

The evidence still to come is operational and financial: resilience through the cycle, durable non-poultry earnings, and cash collected from group customers. It brings the story back to an egg.

↑ Back to Top

XI. The egg, the invoice and the listed company

The SPF egg captures VIL's strengths and limits: it is a technically demanding product, but the company said its plant ran at about half capacity in November 2025.²

Animal Health Products drew on the same scientific base and earned VIL's best segment profit in FY26, but much of its output went to group companies.¹² Related-party trade was substantial, and the controlling shareholder was VIL's largest debtor.⁴

Venky's (India) Limited faces a commodity cycle it cannot control and operates within a larger family group. Both descriptions are accurate. Its specialist strengths and diversification are real, as are its commodity exposure, group dependence and obligation to convert reported sales into cash for minority shareholders.

FY26 showed a recovery. It has not yet shown, segment by segment and year by year, that the listed company keeps the value it creates.

References

1. Integrated Filing, FY26 Audited Standalone Results — NSE, 2026-05-14 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

2. Q2 FY26 Earnings Call Transcript — Venky's (India) Limited, 2025-11-10 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

3. Q4 FY26 Earnings Call Transcript — Venky's (India) Limited, 2026-05-15 ↩↩↩↩↩↩↩↩

4. Annual Report 2024–25 — Venky's (India) Limited, 2025-08-23 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

5. CARE Rating Rationale — CARE Ratings, 2026-01-13 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩

6. Historical Financials and Shareholding — Screener ↩↩↩↩↩↩↩

7. 38th Annual Report 2013–14 — Venky's (India) Limited ↩↩↩↩↩

8. Venkys India: Outcome of board meeting — Moneycontrol, 2014-03-12 ↩

9. Peer and Industry Analysis of Indian Poultry Companies — ICRA ↩

10. Inclusive Poultry Value Chain Project — Asian Development Bank ↩

11. Competition Commission of India Order, Case No. 15 of 2025 — CCI ↩↩↩↩↩

12. CCI directs probe into poultry group on complaint by Maneka Gandhi's NGO — The Economic Times, 2026-04-01 ↩

13. CCI orders probe into Venkateshwara Hatcheries on complaint by People for Animals — Bar and Bench, 2026-04-01 ↩

14. Company sells special eggs for vaccine, strikes it rich — The Times of India, 2021-06-18 ↩↩

15. Chicken prices crash as bird flu worries weigh on consumption — The Economic Times, 2025-03-14 ↩↩

16. Annual Report 2025–26 — Venky's (India) Limited ↩↩

17. Shareholding pattern — The Economic Times ↩